Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2010, Article ID 856542, 4 pages
http://dx.doi.org/10.1155/2010/856542
Research Article

Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients

1Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2College of Pharmacy & Health Sciences, Campbell University, Buies Creek, NC 27506, USA
3Pharmacy Department, Durham Veterans Affairs Medical Center, Durham, NC 27705, USA
4Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA

Received 30 January 2010; Revised 8 June 2010; Accepted 6 September 2010

Academic Editor: Peter P. Koopmans

Copyright © 2010 Emily L. Heil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. S. Sulkowski and D. L. Thomas, “Hepatitis C in the HIV-infected person,” Annals of Internal Medicine, vol. 138, no. 3, pp. 197–207, 2003. View at Google Scholar · View at Scopus
  2. M. Núñez and V. Soriano, “Hepatotoxicity of antiretrovirals: incidence, mechanisms and management,” Drug Safety, vol. 28, no. 1, pp. 53–66, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. M. S. Sulkowski, E. E. Mast, L. B. Seeff, and D. L. Thomas, “Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus,” Clinical Infectious Diseases, vol. 30, supplement 1, pp. S77–S84, 2000. View at Google Scholar · View at Scopus
  4. M. S. Sulkowski, D. L. Thomas, R. E. Chaisson, and R. D. Moore, “Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection,” Journal of the American Medical Association, vol. 283, no. 1, pp. 74–80, 2000. View at Google Scholar · View at Scopus
  5. M. Bonacini, “Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection,” Clinical Infectious Diseases, vol. 38, supplement 2, pp. S104–S108, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. A. R. Lai, K. T. Tashima, and L. E. Taylor, “Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus,” AIDS Patient Care and STDs, vol. 20, no. 10, pp. 678–692, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. M. Den Brinker, F. W. N. M. Wit, P. M. E. Wertheim-van Dillen et al., “Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection,” AIDS, vol. 14, no. 18, pp. 2895–2902, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Núñez, R. Lana, J. L. Mendoza, L. Martín-Carbonero, and V. Soriano, “Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 27, no. 5, pp. 426–431, 2001. View at Google Scholar · View at Scopus
  9. M. S. Sulkowski, D. L. Thomas, S. H. Mehta, R. E. Chaisson, and R. D. Moore, “Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections,” Hepatology, vol. 35, no. 1, pp. 182–189, 2002. View at Publisher · View at Google Scholar · View at PubMed
  10. AIDS Clinical Trials Group, Table of Grading Severity of Adult Adverse Experiences, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, Md, USA, 1996.